Citadel Advisors
ENTX icon

Citadel Advisors’s Entera Bio ENTX Stock Holding History

Citadel Advisors’s Portfolio ENTX Stock Details ENTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-31,000
Closed -$52.7K – 13177
2025
Q1 		$52.7K Buy
+31,000
New +$67.4K ﹤0.01% 12261
2024
Q4 		– Sell
-2,600
Closed -$4.94K – 14717
2024
Q3 		$4.94K Buy
+2,600
New +$4.61K ﹤0.01% 13532
2024
Q2 		– Sell
-3,900
Closed -$6.51K – 14524
2024
Q1 		$6.51K Sell
3,900
-7,200
-65% -$7.95K ﹤0.01% 13665
2023
Q4 		$6.66K Buy
11,100
+400
+4% +$273 ﹤0.01% 13340
2023
Q3 		$7.76K Sell
10,700
-2,000
-16% -$1.47K ﹤0.01% 13241
2023
Q2 		$10.8K Buy
12,700
+3,700
+41% +$3.16K ﹤0.01% 13176
2023
Q1 		$10.4K Sell
9,000
-89,400
-91% -$89.3K ﹤0.01% 13533
2022
Q4 		$71.8K Sell
98,400
-1,100
-1% -$796 ﹤0.01% 11675
2022
Q3 		$103K Buy
99,500
+200
+0.2% +$302 ﹤0.01% 11065
2022
Q2 		$132K Sell
99,300
-1,500
-1% -$3.33K ﹤0.01% 11108
2022
Q1 		$288K Sell
100,800
-32,400
-24% -$77.7K ﹤0.01% 10684
2021
Q4 		$375K Sell
133,200
-19,000
-12% -$71.2K ﹤0.01% 10396
2021
Q3 		$717K Buy
152,200
+43,200
+40% +$222K ﹤0.01% 9009
2021
Q2 		$652K Buy
+109,000
New +$403K ﹤0.01% 9411

Other funds holding ENTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
SEIA
Signature Estate & Investment Advisors Los Angeles, California $5.56B AUM 26.66% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Citadel Advisors's ENTX Position: Q1 2026 in Review

Citadel Advisors increased its Entera Bio (ENTX) stake by 510% in Q1 2026, buying an estimated $288K and bringing the position to 245,577 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #10688.

Citadel Advisors first reported a position in ENTX in Q3 2020 and has held it in 15 quarters since. The position peaked at $402K in Q2 2021. 26 funds tracked by Wall St. Rank hold ENTX as of Q1 2026.

  • Citadel Advisors held 245,577 shares of Entera Bio worth $273K as of Q1 2026.
  • Citadel Advisors bought 205,347 Entera Bio shares in Q1 2026, an estimated $288K.
  • Entera Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10688 holding.
  • Citadel Advisors first reported a position in Entera Bio in Q3 2020 and has held it in 15 quarters since.
  • Citadel Advisors's Entera Bio position peaked at $402K in Q2 2021.
  • 26 funds tracked by Wall St. Rank held Entera Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.